A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) ...

New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.

Zydus Lifesciences Ltd and Torrent Pharmaceuticals Ltd are preparing to enter the fast-growing market for Semaglutide — a ...

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

ICICI Securities is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 34500 in its ...

When a man suddenly collapsed during a televised White house event about weight-loss drugs, it sparked widespread speculation ...

Explore how the rise of weight-loss drugs in India may seem like a quick fix but carry serious health risks. We uncover seven ...

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

Drugs like Wegovy and Ozempic have been in high demand after they were found to help in losing weight. But could a Trump ...